ChemicalBook > CAS DataBase List > Toceranib

Toceranib

Product Name
Toceranib
CAS No.
356068-94-5
Chemical Name
Toceranib
Synonyms
CS-1158;SU-11654;Toceranib;PHA 291639;Toceranib-d8;Toceranib(SU 11654;Toceranib free base;Toceranib,PHA-291639;Toceranib DISCONTINUED;TOCERANIB;SU 11654;PHA 291639
CBNumber
CB32518368
Molecular Formula
C22H25FN4O2
Formula Weight
396.46
MOL File
356068-94-5.mol
More
Less

Toceranib Property

Melting point:
>133°C (dec.)
Boiling point:
596.8±50.0 °C(Predicted)
Density 
1.293
storage temp. 
room temp
solubility 
DMSO (Slightly, Heated), Methanol (Very Slightly, Heated)
pka
11.70±0.20(Predicted)
form 
powder
color 
yellow to orange
More
Less

Hazard and Precautionary Statements (GHS)

Symbol(GHS)
Signal word
Warning
Hazard statements

H315Causes skin irritation

H319Causes serious eye irritation

Precautionary statements

P305+P351+P338IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continuerinsing.

More
Less

N-Bromosuccinimide Price

Sigma-Aldrich
Product number
PZ0338
Product name
Toceranib
Purity
≥98% (HPLC)
Packaging
5MG
Price
$105
Updated
2023/06/20
Sigma-Aldrich
Product number
PZ0338
Product name
Toceranib
Purity
≥98% (HPLC)
Packaging
25MG
Price
$424
Updated
2023/06/20
Cayman Chemical
Product number
17714
Product name
Toceranib
Purity
≥95%
Packaging
1mg
Price
$36
Updated
2024/03/01
Cayman Chemical
Product number
17714
Product name
Toceranib
Purity
≥95%
Packaging
5mg
Price
$155
Updated
2024/03/01
Cayman Chemical
Product number
17714
Product name
Toceranib
Purity
≥95%
Packaging
10mg
Price
$274
Updated
2024/03/01
More
Less

Toceranib Chemical Properties,Usage,Production

Uses

Labelled Toceranib, a multitargeted indolinone receptor tyrosine kinase (RTK) inhibitor. Toceranib exhibited activity against a variety of spontaneous malignancies in canine such as mast cell tumors, mixed mammary carcinomas, soft tissue sarcomas, and multiple myeloma.

Uses

Toceranib is a multitargeted indolinone receptor tyrosine kinase (RTK) inhibitor. Toceranib exhibited activity against a variety of spontaneous malignancies in canine such as mast cell tumors, mixed mammary carcinomas, soft tissue sarcomas, and multiple myeloma.

Biological Activity

toceranib is an inhibitor which blocks various tyrosine kinases expressed on the cell surface. receptor tyrosine kinases (rtks) are excellent candidates for molecular targeted therapy, because they play key roles in controlling cell proliferation and survival and are frequently dysregulated in a variety of malignancies.

Biochem/physiol Actions

Toceranib (SU11654) is a protein tyrosine kinase inhibitor that selectively targets stem cell factor receptor c-kit, including all forms of mutant Kit, as well as PDGFR and VEGFR. Toceranib exhibited Ki values of 5 nM for PDGFR and 6 nM for VEGFR. Toceranib phosphate is approved for use in mast cell cancer in dogs.

in vitro

toceranib inhibited kit phosphorylation and cell proliferation in a dose-dependent manner in the treatment-naïve, parental c2 line (ic50 < 10 nm). in addition, chronic toc exposure resulted in c-kit mrna and kit protein overexpression in the toc-resistant sublines [1].

in vivo

fourteen dogs with advanced mast cell tumors (mcts) were enrolled in a prevoius study, among which 11 dogs were evaluable for kit target modulation. of these, eight mcts showed reduced levels of phosphorylated kit relative to total kit after treatment with toceranib, compared with pretreatment biopsies. all four evaluable mcts expressing itd mutant c-kit showed modulation of kit phosphorylation, as did four of seven tumors expressing non-itd c-kit. [2].

References

[1] halsey ch, gustafson dl, rose bj, wolf-ringwall a, burnett rc, duval dl, avery ac, thamm dh. development of an in vitro model of acquired resistance to toceranib phosphate (palladia®) in canine mast cell tumor. bmc vet res. 2014;10:105. doi: 10.1186/1746-6148-10-105.
[2] pryer nk, lee lb, zadovaskaya r, yu x, sukbuntherng j, cherrington jm, london ca. proof of target for su11654: inhibition of kit phosphorylation in canine mast cell tumors. clin cancer res. 2003;9(15):5729-34.

Toceranib Preparation Products And Raw materials

Raw materials

Preparation Products

More
Less

Toceranib Suppliers

Shanghai Boyle Chemical Co., Ltd.
Tel
Fax
86-21-57758967
Email
sales@boylechem.com
Country
China
ProdList
2923
Advantage
55
J & K SCIENTIFIC LTD.
Tel
010-82848833 400-666-7788
Fax
86-10-82849933
Email
jkinfo@jkchemical.com
Country
China
ProdList
96815
Advantage
76
ZHIWE CHEMTECH CO LTD
Tel
021-20221225 13917446399
Fax
QQ:115820162
Email
sales@zhiwe.net
Country
China
ProdList
580
Advantage
61
Chemsky (shanghai) International Co.,Ltd
Tel
021-50135380
Email
shchemsky@sina.com
Country
China
ProdList
15421
Advantage
60
Jinan Trio PharmaTech Co., Ltd.
Tel
+86 (531) 88811783
Fax
+86 (531) 55696010 QQ 1762738062
Email
sales@trio-pharmatech.com (International market)
Country
China
ProdList
1856
Advantage
62
Shanghai Hope Chem Co., Ltd.,
Tel
+21-18501659228 18501659228
Fax
sales@hope-chem.com
Email
info@hope-chem.com
Country
China
ProdList
433
Advantage
55
Nanjing JinruiJiuAn Biotechnology Co., Ltd.
Tel
025-58196018 800028039
Fax
025-83453306
Email
sales@fartop.net
Country
China
ProdList
2231
Advantage
55
Shanghai T&W Pharmaceutical Co., Ltd.
Tel
+86 21 61551611
Fax
+86 21 50676805
Country
China
ProdList
9901
Advantage
58
Haoyuan Chemexpress Co., Ltd.
Tel
021-58950125
Fax
(86) 21-58955996
Email
info@chemexpress.com
Country
China
ProdList
7553
Advantage
61
UHN Shanghai Research & Development Co., Ltd.
Tel
021-58958002 18930822973
Fax
+86 (21) 5895-8628
Email
SALES@UHNSHANGHAI.COM
Country
China
ProdList
977
Advantage
58

356068-94-5, ToceranibRelated Search:


  • (Z)-5-(5-Fluoro-2-oxo-2,3-dihydro-1H-indol-3-ylidenemethyl)-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]-1H-pyrrole-3-carboxamide
  • CS-1158
  • SU 11654; PHA 291639; SU11654; SU-11654; PHA-291639; PHA291639
  • SU-11654
  • Toceranib
  • (Z)-5-[(5-Fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-(2-pyrrolidin-1-ylethyl)-1H-pyrrole-3-carboxamide
  • 5-(5-Fluoro-2-oxo-1,2-dihydroindol-(3Z)-ylideneMethyl)-2,4-diMethyl-1H-pyrrole-3-carboxylic Acid (2-(Pyrrolidin-1-yl)ethyl)aMide
  • 5-[(Z)-(5-Fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)Methyl]-2,4-diMethyl-N-[2-(1-pyrrolidinyl)ethyl]-1H-pyrrole-3-carboxaMide
  • PHA 291639
  • 5-(5-Fluoro-2-oxo-1,2-dihydroindol-(3Z)-ylideneMethyl)-2,4-diMethyl-1H-pyrrole-3-carboxylic Acid (2-(Pyrrolidin-1-yl-d8)ethyl)aMide
  • 5-[(Z)-(5-Fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)Methyl]-2,4-diMethyl-N-[2-(1-pyrrolidinyl-d8)ethyl]-1H-pyrrole-3-carboxaMide
  • Toceranib-d8
  • Toceranib (PHA 291639, SU 11654)
  • Toceranib,PHA-291639
  • 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(pyrrolidin-1-yl)ethyl]-1H-pyrrol-3-carboxamide
  • Toceranib(SU 11654
  • TOCERANIB;SU 11654;PHA 291639
  • (Z)-5-((5-Fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-N-(2-(pyrrolidin-1-yl)ethyl)-1H-p
  • 5-HYDROXY-2-(4-HYDROXY-3-METHOXYPHENYL)-7-METHOXY-4H-CHROMEN-4-ON<WBR />E
  • 1H-Pyrrole-3-carboxaMide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)Methyl]-2,4-diMethyl-N-[2-(1-pyrrolidinyl)ethyl]-
  • Toceranib free base
  • Toceranib DISCONTINUED
  • (Z)-5-((5-Fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-N-(2-(pyrrolidin-1-yl)ethyl)-1H-pyrrole-3-carboxamide
  • 356068-94-5
  • 256068-94-5